effects of consumption of bread fortified with soy bean flour on metabolic profile in type 2 diabetic women: a cross-over randomized controlled clinical trial

Diabetes mellitus is one of the most common chronic diseases in the world and has become a major threat for global health. Recent studies reported that the soy has beneficial effects in diabetic mellitus patients. The aim of this study was to assess the effects of soybean flour fortified bread consumption on metabolic profile in type 2 diabetic women. This randomized, cross-over, controlled clinical trial was carried out in 30 type 2 diabetic women. At first, a 2-week run-in period was applied. Then, participants were randomly assigned to either intervention or control groups. Participants in the intervention group were asked to replace 120 g of soybean flour fortified bread with the same amount of their usual bread intake or other cereal products for 6 weeks. After a 4 weeks washout period, participants were crossed over for another 6 weeks. Mean [+/- standard deviation] age and body mass index of subjects was 45.7 +/- 3.8 years and 29.5 +/- 3.9 kg/m[2], respectively. The results of our study showed no significant effects of soybean flour fortified bread on metabolic profile. We found a reduction in serum triglycerides [change difference: -3.7, P = 0.82], serum low-density lipoprotein-cholesterol [change difference:-11.2, P = 0.50], insulin [change difference:-3.6, P = 0.7], and homeostatic model assessment of insulin resistance [change differences: -0.57, P = 0.45] after 6 weeks but these changes were not statistically significant. No significant effects of soybean flour fortified bread on serum concentrations of fasting blood sugar, glycated hemoglobin, high-density lipoproteins and total cholesterol levels were found. Six weeks consumption of soybean flour fortified bread among diabetic patients had no significant effects on metabolic profile

Effect of honey vinegar syrup on blood sugar and lipid profile in healthy subjects

The impact of honey or vinegar on several metabolic abnormalities has been studied separately, a mixture of these two ingredients known as honey vinegar syrup [HVS] has not been investigated previously so far. The aim of this study was to assess the impact of HVS consumption [Iranian's traditional syrup] on glycemic parameters and lipid profiles in healthy individuals. We conducted a 4-week, randomized, controlled, parallel study consisting of two groups of nonobese healthy volunteers. All subjects were asked to stay on their normal diet. Intervention group [n = 36] received a cup of HVS daily in the evening snack for 4-week [250 cc syrup contains 21.66 g honey vinegar]. Assessments of fasting blood sugar [FBS], insulin, homeostasis model assessment of insulin resistance [HOMA-IR], total cholesterol [TC], triglyceride [TG], high-density lipoprotein cholesterol [HDL-C] and low-density lipoprotein cholesterol [LDL-C] were conducted at the baseline and after 4-week of study. We observed no significant effect of HVS on FBS, HOMA-IR, LDL-C and TG. A significant effect of HVS was found on increasing fasting insulin and HOMA-IR and reduction in TC level only in intervention group [DELTA =3.39 P = 0.01, DELTA =1.65 P = 0.03, DELTA = -9.43 P = 0.005, respectively]. Changes of FBS, TG and LDL-C were 1.83 mg/dl, -1.53 mg/dl and - 3.99 mg/dl respectively in the intervention group. These changes were not significant. An unfavorable and significant reduction in HDL-C level was also observed between two groups [DELTA = -4.82 P < 0.001 in the intervention group]. Honey vinegar syrup increased fasting insulin level and decreased TC level in the intervention group. HVS had an unfavorable effect on HDL-C level. Further prospective investigations are warranted to confirm these findings

effects of quercetin supplementation on body composition, exercise performance and muscle damage indices in athletes

Flavonoids comprise a large group of plant metabolites, 6,000 of which have been identified to date. Some studies have shown the increased aerobic performance and maximal oxygen consumption [VO[2max]] and therefore fitness following quercetin intake as a result of elevated number of intracellular mitochondria caused by the flavonoid. This double-blind clinical trial comprised 60 male students having an athletic history of at least 3 years. Body composition, exercise performance, and some blood biomarkers were analyzed. The individuals were selected by convenient sampling, and then were assigned into four groups of equal number by using permuted block randomization. The first to fourth groups received a 500 mg supplemental quercetin capsule plus a 250 mg vitamin C pill, a 500 mg supplemental quercetin capsule plus a 250 mg placebo vitamin C pill, a 500 mg placebo quercetin capsule plus a 250 mg vitamin C pill, and a 500 mg placebo quercetin capsule plus a 250 mg placebo vitamin C pill, respectively, daily for 8 weeks. The participants were asked to continue their routine diet and physical activity during the study and they were monitored through phone calls or text messages. Lean body mass, total body water, basal metabolic rate, and total energy expenditure increased significantly in the quercetin group after intervention. On the other hand, VO[2max] increased in the "quercetin" and "quercetin + vitamin C" groups following the intervention, non-significantly. Our findings suggest that supplementation with quercetin in athletes may improve some indices of performance

Neuroprotective effects of erythropoietin in acute ischemic stroke

Ischemic brain strokes consist two-thirds of strokes and their complications bear a lot of disability for patient and society. In this study, we seek for effect of Erythropoietin on ischemic brain stroke's outcomes according to National Institutes of Health Stroke Scale [NIHSS] changes. This study is a RCT [randomized clinical trial]. All patients with focal neurologic deficit with primary suspicion of brain stroke undergone neuroimaging evaluations. After confirmation of new ischemic brain stroke, the patients with inclusion criteria's randomized into two groups of cases and controls. NIHSS was defined for each patient and all patients received a routine treatment protocol. Erythropoietin 16,000 IU as a bolus intravenous dose was given to case patients as soon as neuroimaging study confirmed new ischemic stroke and continued as 8000 IU each 12 h up to total dose of 56,000 IU during 3 days. Patients re-evaluated at days 14 and 28 and NIHSS was assessed by another neurologist blinded to patient's group. Finally, NIHSS changes of both groups compared with each other's. Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in NIHSS [P= 0.0001]. This effect was of value in level of consciousness Commands [P= 0.024], facial palsy [P= 0.003], motor arm [P= 0.0001], motor leg [P= 0.0001], sensory [P= 0.009], and best language [P= 0.023]. Administration of high-dose erythropoietin in first 24 h can be effective on reduction of ischemic stroke complication. A larger scale clinical trial is warranted